Printer Friendly

MERIDIAN RELEASES FIFTH PREMIER ENZYME IMMUNOASSAY

 MERIDIAN RELEASES FIFTH PREMIER ENZYME IMMUNOASSAY
 CINCINNATI, Oct. 14 /PRNewswire/ -- Meridian Diagnostics, Inc.


(NASDAQ/NMS: KITS) today announced that its new test which identifies the disease blastomycosis has been cleared by the FDA pre-market notification process and is available for commercial distribution. This infectious fungus, "Blastomyces dermatitides," produces symptoms from those of a mild flu-like disease to severe respiratory complications and potential mortality. Meridian's product replaces a more tedious, time consuming and significantly less accurate testing procedure. The new Premier "Blastomyces" EIA test provides improved accuracy and produces results in as little as 65 minutes as compared to several hours or an overnight procedure. The company will begin to ship product within the next several weeks.
 Jerry L. Ruyan, chief executive officer said, "This is the last of a complete panel of new enzyme immunoassay products which we developed for various serious fungal diseases. This panel will provide a very accurate and simple diagnostic tool for the diagnosis of patients suffering from unknown common fungal illnesses."
 Meridian Diagnostics, Inc. develops, manufactures and markets a variety of immunodiagnostic test kits, purified reagents such as antigens and monoclonal and polyclonal antibodies, and related diagnostic products. The company is a leader in the area of rapid diagnosis of infectious human diseases. All Meridian products are used outside the human body and require little or no special instrumentation or equipment. Domestic and international market segments consist of hospital, commercial and reference laboratories, and physicians' offices. The company has a leading market position in fungal serology, and is the leader in parasite and bacterial collection, preservation and transportation systems. The company's shares are traded through NASDAQ/NMS (Symbol: KITS).
 -0- 10/14/92
 /CONTACT: Jerry L. Ruyan of Meridian Information Diagnostics, Inc., 513-271-3700/
 (KITS) CO: Meridian Information Diagnostics, Inc. ST: Ohio IN: MTC SU: PDT


BM -- CL008 -- 9774 10/14/92 10:42 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 14, 1992
Words:309
Previous Article:SCIENTIFIC SOFTWARE COMPLETES FINANCING
Next Article:GM CHAIRMAN UPDATE
Topics:


Related Articles
MERIDIAN RECEIVES FDA CLEARANCE TO MARKET NEW IMMUNOCARD PRODUCT TO DIAGNOSE INFECTIOUS MONONUCLEOSIS
MERIDIAN COMPLETES SECOND ACQUISITION OF DIAGNOSTIC PRODUCTS FROM AN AFFILIATE OF ORTHO DIAGNOSTIC SYSTEMS, INC., A JOHNSON & JOHNSON COMPANY
MERIDIAN RELEASES THIRD IMMUNOCARD PRODUCT WITH TWO MORE IN DEVELOPMENT
MERIDIAN RELEASES FOURTH IMMUNOCARD PRODUCT
Sanko Junyaku, Eisai and Fujirebio Sign Joint Research Agreement for Development of New KL-6 Test Kit.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters